Enovis (NYSE:ENOV) Issues Earnings Results, Beats Expectations By $0.11 EPS

Enovis (NYSE:ENOV) released its earnings results on Thursday. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11, FiscalAI reports. The company had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. Enovis’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 earnings per share.

Here are the key takeaways from Enovis’ conference call:

• Enovis delivered 5% organic sales growth in Q3, led by 6% growth in Recon; P&R grew 3%. Adjusted EPS rose 17% to $0.88, while adjusted EBITDA margin expanded 120 basis points to 18.5%.
• The company raised its adjusted EBITDA outlook to $428 million–$438 million and adjusted EPS outlook to $3.58–$3.79, while maintaining expected organic growth of about 5%. It also reaffirmed its goal of greater than 25% free-cash-flow conversion in 2026.
• Management described markets as volatile, citing choppy U.S. hip and knee demand, challenging Western European conditions, and Middle East conflict that reduced total company growth by about 40 basis points. Inflation in raw materials, freight and distribution also pressured costs, partly offset by tariff refunds.
• Enovis expects to close its eCential Robotics acquisition by year-end and is investing in talent and technology ahead of integration. Management expects to bring a knee robot to market within two years, with shoulder to follow, and said customer feedback has been encouraging.
• The board authorized a $200 million share repurchase program, which management said it will use opportunistically while targeting leverage of 2.5–3.5 times. Net leverage was 2.9 times at quarter-end and is expected to rise about half a turn after the eCential deal closes.

Enovis Stock Performance

Shares of Enovis stock traded down $1.46 on Friday, reaching $27.16. 2,304,734 shares of the company were exchanged, compared to its average volume of 1,449,886. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of 6.16 and a beta of 1.31. Enovis has a 1-year low of $16.70 and a 1-year high of $32.41. The company’s 50-day moving average is $19.91 and its two-hundred day moving average is $23.09.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ENOV. Canaccord Genuity Group lowered their price objective on shares of Enovis from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Wells Fargo & Company boosted their price objective on shares of Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Enovis currently has an average rating of “Moderate Buy” and a consensus price target of $38.62.

Insider Activity

In other news, insider Oliver Engert bought 2,660 shares of Enovis stock in a transaction on Friday, September 4th. The stock was purchased at an average cost of $18.80 per share, with a total value of $50,008.00. Following the purchase, the insider directly owned 63,898 shares of the company’s stock, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Damien Mcdonald acquired 13,035 shares of Enovis stock in a transaction dated Friday, September 4th. The shares were acquired at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the transaction, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This trade represents a 5.57% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 23,293 shares of company stock worth $449,599. 2.90% of the stock is currently owned by insiders.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.